New combination treatment targets pre-leukemia stem cells

September 12, 2018, CU Anschutz Medical Campus
New combination treatment targets pre-leukemia stem cells
Craig T. Jordan and colleagues characterize and target pre-leukemia stem cells. Credit: University of Colorado Cancer Center

Your body's blood cells are manufactured by hematopoietic stem cells in bone marrow. But just as regular, mature cells can become cancerous, so too can stem cells. When hematopoietic stem cells mutate in specific ways, the result can be damaged stem cells that create a type of pre-leukemic condition known as myelodysplastic syndrome, or MDS. On its own, MDS is a chronic condition that results in symptoms like anemia. In early stages, MDS can usually be managed with supportive care. However, as the disease progresses, about one in three cases of high-risk MDS will evolve into acute myeloid leukemia (AML), an extremely dangerous form of blood cancer that can be lethal.

There is no perfect treatment for MDS—current strategies include chemotherapy, which tends to be ineffective against cancer , and bone marrow transplant, which requires lengthy hospitalization, can include significant and lasting side effects, and is not appropriate for most MDS patients who tend to be older or more frail. A University of Colorado Cancer Center study published today in Nature Communications takes aim at the stem that create MDS and, eventually, AML. The study shows that MDS stem cells dramatically increase their energy use and production of proteins. And it shows that drugs that target these processes result in the death of MDS stem cells, while leaving healthy unharmed.

"Current treatments for MDS are not designed to specifically target the malignant stem cells. This makes treatment much like mowing over weeds without killing the root. Patients can achieve some benefit from chemotherapy, but eventually the MDS stem cells drive progression of the disease," says Craig T. Jordan, Ph.D., investigator at CU Cancer Center, Chief of the Division of Hematology and the Nancy Carroll Allen Professor of Hematology at the CU School of Medicine.

The story starts with a called CD123. Previous work has shown that AML stem cells tend to be coated with CD123. The study's lead investigator and first author Brett Stevens, Ph.D., proposed that CD123 might also be detectable in patients with MDS, and therefore act as way to distinguish MDS stem cells from normal stem cells. In a series of laboratory studies, Stevens also showed that stem cells with CD123 have unique properties.

Genes rarely function alone and instead are members of "pathways" that have certain larger functions. To zoom out from the level of genes to the level of pathways, Stevens, Jordan and colleagues used a technique called gene set enrichment analysis to cluster the genetic changes they saw in CD123+ cells by their function.

"This let us explore not just what is turned on and off, but what these adjustments do, functionally, for the cell," Stevens says.

The major pathway magnified in CD123+ cells was one driving the action of ribosomes. Ribosomes make proteins, and the genetic changes in CD123+ cells meant that ribosomes in these cells were making far more proteins than they should. Interestingly, these pre- were making many more proteins without making many more cells. This is important because chemotherapy is designed to kill rapidly-dividing cells. These CD123+ pre-leukemia stem cells are not rapidly-dividing, and so they resist chemotherapy.

Another significantly magnified pathway in CD123+ cells had to do with energy. In cells, mitochondria use a process called oxidative phosphorylation to make ATP, which is the major unit of cellular energy. The more oxidative phosphorylation, the more ATP. And in CD123+ stem cells, there was much more oxidative phosphorylation.

Here is the important part: While CD123 is not directly druggable, the pathways of increased protein production and oxidative phosphorylation are.

Omacetaxine mepesuccinate is a protein synthesis inhibitor, FDA approved to treat chronic myeloid leukemia. When the group treated CD123+ stem cells with omacetaxine, it blocked protein production in these cells and the cells died.

"We have seen the usefulness of omacetaxine in CML and even hints of its activity in AML, and now we may see why this drug works. It looks like omacetaxine stops the protein synthesis that CD123+ stem cells need to live," Jordan says.

Secondly, the group targeted oxidative phosphorylation, the process that CD123+ stem cells were using to boost ATP production. As with protein synthesis, drugs exist to block oxidative phosphorylation. One of these drugs is venetoclax. Venetoclax blocked oxidative phosphorylation and killed most but not all patient samples of CD123+ stem cells.

When the group added omacetaxine (to block protein synthesis) to venetoclax (to block oxidative phosphorylation), the combination was highly effective against CD123+ leukemia stem cells. Importantly, because it is only these pre-leukemic stem cells and not healthy stem cells that rely on protein synthesis and , it is only these cancerous cells and not healthy cells that are killed. Both drugs are already FDA-approved for use in human patients, raising the possibility of immediate use.

"We see not only that this combination works, but why it works. We hope that omacetaxine and venetoclax will be a potent combination against advanced MDS," Jordan says.

Explore further: Some blood stem cells are better than others

More information: Brett M. Stevens et al, Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes, Nature Communications (2018). DOI: 10.1038/s41467-018-05984-x

Related Stories

Some blood stem cells are better than others

May 30, 2018
In your body, blood stem cells produce approximately 10 billion new white blood cells, which are also known as immune cells, each and every day. Even more remarkably, if some of these blood stem cells fail to do their part, ...

Without 'yoga and chardonnay' leukemia stem cells are stressed to death

June 14, 2018
Change is stressful. The change that a healthy blood stem cell undergoes to become a leukemia stem cell (LSC) is no exception—think of healthy blood stem cells as young professionals and the transformation into an LSC as ...

Single surface protein boosts multiple oncogenic pathways in acute myeloid leukemia

May 17, 2018
Researchers from the Albert Einstein College of Medicine in New York have discovered that a signaling protein elevated in patients with acute myeloid leukemia (AML) plays a much wider role in the disease than previously thought. ...

As leukemia evolves, stem cells hold keys to newer therapies

August 30, 2016
A recent study by University of Rochester Medical Center researchers proves why leukemia is so difficult to treat and suggests that the current approach to drug development should be adjusted to target a broader range of ...

Inhibiting CDK6 prevents leukemic relapse

January 27, 2015
Despite enormous progress in cancer therapy, many patients still relapse because their treatment addresses the symptoms of the disease rather than the cause, the so-called stem cells. Work in the group of Veronika Sexl at ...

Recommended for you

Separated entry and exit doors for calcium keep energy production smooth in the powerhouses of heart cells

September 18, 2018
Stress demands the heart to work harder and faster. To keep pace, the muscle must make its fuel at an accelerated rate. Bursts of calcium entering mitochondria—the cell's powerhouses—normally help control energy output, ...

First gut bacteria may have lasting effect on ability to fight chronic diseases

September 18, 2018
New research showing that the first bacteria introduced into the gut have a lasting impact may one day allow science to adjust microbiomes—the one-of-a-kind microbial communities that live in our gastrointestinal tracts—to ...

A new defender for your sense of smell

September 18, 2018
New research from the Monell Center increases understanding of a mysterious sensory cell located in the olfactory epithelium, the patch of nasal tissue that contains odor-detecting olfactory receptor cells. The findings suggest ...

Small molecule plays big role in weaker bones as we age

September 18, 2018
With age, expression of a small molecule that can silence others goes way up while a key signaling molecule that helps stem cells make healthy bone goes down, scientists report.

Sperm quality study updates advice for couples trying to conceive

September 17, 2018
Could doctors at fertility clinics be giving men bad advice? Dr. Da Li and Dr. XiuXia Wang, who are clinician-researchers at the Center for Reproductive Medicine of Shengjing Hospital in Shenyang in northeast China, think ...

Antioxidant found to be effective in treating mice with osteoarthritis

September 14, 2018
A team of researchers in Belgium and the Netherlands has found that feeding a common antioxidant to test mice was effective in treating osteoarthritis. In their paper published in Science Translational Medicine, the group ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.